Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. (Q42515604)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

title

Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

Roberto Attanasio

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

author name string

R Cozzi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

M Barausse

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

M Sberna

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

A Lodrini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

G Lasio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

publication date

1 December 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

5 December 2019

page(s)

231-238

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11788011%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1012832230598

5 December 2019

exact match

0 references

cites work

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.

1 reference

12 December 2020

Current treatment guidelines for acromegaly

1 reference

12 December 2020

SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged action

1 reference

12 December 2020

Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors

1 reference

12 December 2020

Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men

1 reference

12 December 2020

Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months.

1 reference

12 December 2020

Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide

1 reference

12 December 2020

Depot somatostatin analogs--a new first line therapy for acromegaly

1 reference

12 December 2020

Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly

1 reference

12 December 2020

Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide

1 reference

12 December 2020

Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide

1 reference

12 December 2020

GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.

1 reference

12 December 2020

Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience

1 reference

12 December 2020

Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly

1 reference

12 December 2020

Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly

1 reference

12 December 2020

The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.

1 reference

12 December 2020

Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients

1 reference

12 December 2020

[Treatment of acromegaly with sustained-release lanreotide. A new somatostatin analog]

1 reference

12 December 2020

Octreotide as primary therapy for acromegaly.

1 reference

12 December 2020

Medical therapy for acromegaly.

1 reference

12 December 2020

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate

1 reference

12 December 2020

Surgical management of acromegaly

1 reference

12 December 2020

Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients

1 reference

12 December 2020

Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group

1 reference

12 December 2020